Current
16.9×
5-Year Average
14.9×
All-Time High
27.2×
All-Time Low
8.1×
P/FCF Ratio daily chart for Quest Diagnostics (DGX)
Jun 8, 2021 – Jun 5, 2026 · 1,255 trading days
Historical P/FCF Ratio for Quest Diagnostics (DGX) from 2001 to 2025
| 2025 | $19.26B | $1.36B | 14.2× | -4.2× | |
| 2024 | $16.75B | $909.00M | 18.4× | +0.5× | |
| 2023 | $15.44B | $864.00M | 17.9× | +4.4× | |
| 2022 | $17.68B | $1.31B | 13.5× | +1.9× | |
| 2021 | $21.11B | $1.83B | 11.5× | +1.4× | |
| 2020 | $16.09B | $1.59B | 10.1× | -6.8× | |
| 2019 | $14.31B | $843.00M | 17.0× | +3.1× | |
| 2018 | $11.32B | $817.00M | 13.9× | -0.7× | |
| 2017 | $13.39B | $923.00M | 14.5× | -1.8× | |
| 2016 | $12.68B | $776.00M | 16.3× | -2.3× | |
| 2015 | $10.17B | $547.00M | 18.6× | +3.2× | |
| 2014 | $9.72B | $630.00M | 15.4× | -3.1× | |
| 2013 | $7.82B | $421.00M | 18.6× | +9.4× | |
| 2012 | $9.25B | $1.00B | 9.2× | -3.3× | |
| 2011 | $9.19B | $733.87M | 12.5× | +3.0× | |
| 2010 | $8.72B | $912.68M | 9.6× | -3.6× | |
| 2009 | $10.88B | $830.49M | 13.1× | +1.5× | |
| 2008 | $9.83B | $850.37M | 11.6× | -2.9× | |
| 2007 | $10.24B | $707.82M | 14.5× | +1.0× | |
| 2006 | $10.25B | $758.47M | 13.5× | -2.8× | |
| 2005 | $10.21B | $627.31M | 16.3× | +0.9× | |
| 2004 | $9.57B | $622.65M | 15.4× | -0.1× | |
| 2003 | $7.54B | $488.16M | 15.4× | +2.9× | |
| 2002 | $5.52B | $441.18M | 12.5× | -9.0× | |
| 2001 | $6.83B | $316.82M | 21.6× | — |
- 202514.2×
- 202418.4×
- 202317.9×
- 202213.5×
- 202111.5×
- 202010.1×
- 201917.0×
- 201813.9×
- 201714.5×
- 201616.3×
- 201518.6×
- 201415.4×
- 201318.6×
- 20129.2×
- 201112.5×
- 20109.6×
- 200913.1×
- 200811.6×
- 200714.5×
- 200613.5×
- 200516.3×
- 200415.4×
- 200315.4×
- 200212.5×
- 200121.6×
About P/FCF Ratio at Quest Diagnostics (DGX)
Quest Diagnostics (DGX) P/FCF ratio is 16.9× as of June 5, 2026. The 5-year average is 14.9×. The sector median currently stands at 19.8×. The current ratio is at the 64th percentile of its own 10-year history.
Quest Diagnostics (DGX) historical P/FCF ratio has ranged from a low of 8.1× (2021) to a high of 27.2× (2024) in the available daily series.
The price-to-free-cash-flow (P/FCF) ratio compares a company's market capitalisation to its trailing twelve-month (TTM) free cash flow. It is calculated as market cap ÷ TTM free cash flow, where free cash flow = operating cash flow − capital expenditures. Because FCF cannot be inflated by non-cash accounting items, P/FCF is often considered a cleaner measure of "earnings-power valuation" than P/E — especially for capital-intensive businesses where depreciation diverges from real cash outflows.
Quest Diagnostics P/FCF Ratio by Year
Quest Diagnostics P/FCF Ratio 2025: 14.2×
Quest Diagnostics (DGX) P/FCF ratio in 2025 was 14.2×, contracted from 18.4× the prior year.
Quest Diagnostics P/FCF Ratio 2024: 18.4×
Quest Diagnostics (DGX) P/FCF ratio in 2024 was 18.4×, expanded from 17.9× the prior year.
Quest Diagnostics P/FCF Ratio 2023: 17.9×
Quest Diagnostics (DGX) P/FCF ratio in 2023 was 17.9×, expanded from 13.5× the prior year.
Quest Diagnostics P/FCF Ratio 2022: 13.5×
Quest Diagnostics (DGX) P/FCF ratio in 2022 was 13.5×, expanded from 11.5× the prior year.
Quest Diagnostics P/FCF Ratio 2021: 11.5×
Quest Diagnostics (DGX) P/FCF ratio in 2021 was 11.5×.
Sector peers by P/FCF Ratio — chart
Current ratio vs. sector peers. Highlighted bar is this company.
Sector peers by P/FCF Ratio — table
Healthcare peers of Quest Diagnostics (DGX), ranked by P/FCF ratio.
| 18.5× | |
| 17.8× | |
| 17.8× | |
| 16.9× | |
| 16.9× | |
| 16.7× | |
| 16.4× | |
| 15.9× | |
| 14.0× | |
| 13.5× | |
| 12.9× | |
| 12.5× | |
| 12.4× | |
| 12.2× | |
| 12.1× | |
| 11.3× | |
| 10.7× | |
| 10.4× | |
| 10.3× | |
| 10.0× | |
| 9.6× | |
| 9.1× | |
| 9.1× | |
| 6.9× | |
| 2.5× |
- 18.5×
- 17.8×
- 16.9×
- 16.7×
- 16.4×
- 13.5×
- 12.9×
- 12.4×
- 10.7×
- 10.3×
- 9.1×
- 9.1×
- 6.9×
- 2.5×
Frequently asked questions
Quest Diagnostics (DGX) Key Financials
Charts, filings, and peer comparison for every metric